Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVENUE THERAPEUTICS, INC.ATXI · Entity 8537 | Director | December 03, 2018 | December 12, 2018 |
| IMMUNE PHARMACEUTICALS INCIMNP · Entity 151953 | Director | January 25, 2017 | January 27, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVENUE THERAPEUTICS, INC.
Report date December 03, 2018 · Filed December 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 79,663 |
Last balance in matching sequence
After 2018-12-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-12-03 · Purchase · Acquired 10,000 · Balance 74,663 F1: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on December 3, 2018 was $5.4734 to $5.4774. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2: Includes 64,663 shares of restricted stock. Row 2 · 2018-12-10 · Purchase · Acquired 5,000 · Balance 79,663 F2: Includes 64,663 shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on December 3, 2018 was $5.4734 to $5.4774. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.
F2: Includes 64,663 shares of restricted stock.
IMMUNE PHARMACEUTICALS INC
Report date January 25, 2017 · Filed January 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.20 · Expires 2027-01-25 | Direct | 700,000 |
Reported balance
After 2017-01-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-25 · Grant · Acquired 500,000 · Balance 700,000 F1: The stock options shall vest in equal quarterly installments over a one-year period from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options shall vest in equal quarterly installments over a one-year period from the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Journey Medical Corp
Report date November 07, 2023 · Filed December 08, 2023
Section 16 reporting ended · disclosed 2023-12-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 114,217 |
Last balance in matching sequence
After 2023-11-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-11-07 · Sale · Disposed 2,245 · Balance 114,472 F1: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. Row 2 · 2023-11-08 · Sale · Disposed 255 · Balance 114,217 F1: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2023 Filed Nov 29, 2023 16:42 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 1,745 | $5.22 | $9,108.90 |
DisclosureSEC source: 0001104659-23-122072 · tm2331786-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,727 Read SEC document |
| November 08, 2023 Filed Dec 8, 2023 17:01 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 255 | $3.76 | $958.80 |
DisclosureSEC source: 0001104659-23-124743 · tm2332498-1_4seq1.xml · nonDerivative · entry 2 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,217 F1 · balance_after: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. Read SEC document |
| November 07, 2023 Filed Dec 8, 2023 17:01 UTC | Journey Medical Corp DERM · Entity 6273 | SaleCommon Stock, par value $0.0001 per share | 2,245 | $3.48 | $7,812.60 |
DisclosureSEC source: 0001104659-23-124743 · tm2332498-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,472 F1 · balance_after: The reporting person realized short-swing profits under Section 16(b) of the Securities Exchange Act of 1934, as amended, as a result of sales of the Issuer's common stock reported herein, as well as the sales reported on a Form 4 filed November 29, 2023, being matched against non-exempt purchases of 4,245 shares of common stock made on September 21, 2023. Accordingly, the reporting person has paid to the Issuer (i) $1,724.98 in connection with the matched sales reported herein and (ii) $4,189.95 in connection with the matched sales made on November 28, 2023, representing the aggregate short-swing profit realized by the reporting person, less transaction costs. Includes 10,000 restricted units of which will vest in full on July 1, 2024 and 27,472 restricted stock units of which will vest on July 21, 2024. Read SEC document |
| October 06, 2023 Filed Oct 10, 2023 16:41 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, par value $0.0001 per share | 15,000 | $2.98 | $44,700.00 |
DisclosureSEC source: 0001104659-23-108323 · tm2328171-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,472 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on October 6, 2023, was $2.97 to $2.99. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 16:01 UTC | Journey Medical Corp DERM · Entity 6273 | PurchaseCommon Stock, par value $0.0001 per share | 30,000 | $2.97 | $89,100.00 |
DisclosureSEC source: 0001104659-23-103509 · tm2326865-1_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,472 F1 · price: Reflects the weighted average purchase price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one-dollar price range. The range of prices for the sale transactions on September 21, 2023, was $2.82 to $3.00. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 21, 2023 Filed Jul 25, 2023 16:06 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 27,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-083834 · tm2321950-2_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,717 F1 · shares: On July 21, 2023, the reporting person was granted 27,472 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2024. F2 · balance_after: Includes 61,717 restricted stock units, 27,472 units of which will vest in full on July 21, 2024 as set forth in footnote 1, and 10,000 units of which will vest on July 1, 2024. Read SEC document |
| July 21, 2022 Filed Jul 25, 2022 09:38 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCommon Stock, par value $0.0001 per share | 14,245 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082289 · tm2221508-5_4seq1.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,245 F1 · shares: On July 21, 2022, the reporting person was granted 14,245 restricted stock units pursuant to the Issuer's 2015 Stock Plan, which will vest in full on July 21, 2023. F2 · balance_after: Includes 34,245 restricted stock units, 14,245 of which will vest as set forth in footnote 1, and 20,000 of which will vest in increments as follows: (1) 10,000 units on July 1, 2023, and (2) 10,000 units on July 1, 2024. Read SEC document |
| January 14, 2022 Filed Apr 4, 2022 16:49 UTC | Journey Medical Corp DERM · Entity 6273 | GrantCOMMON STOCK | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042280 · tm2211324-10_4.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The 30,000 restricted stock units relating to this grant will vest in three increments as follows: (1) 10,000 units on July 1, 2022, (2) 10,000 units on July 1, 2023, and (3) 10,000 units on July 1, 2024. F2 · balance_after: Includes restricted stock units, which vest over various time periods as set forth in footnote 1. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 13:15 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 5,000 | $4.76 | $23,800.00 |
DisclosureSEC source: 0001144204-18-064217 · tv508813_form4.xml · nonDerivative · entry 2 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,663 F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| December 03, 2018 Filed Dec 12, 2018 13:15 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | PurchaseCommon Stock | 10,000 | $5.48 | $54,754.00 |
DisclosureSEC source: 0001144204-18-064217 · tv508813_form4.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,663 F1 · price: Reflects the weighted average purchase price of multiple same-way open market purchase transactions effected by the Reporting Person on the same day at different prices through a purchase order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the purchase transactions on December 3, 2018 was $5.4734 to $5.4774. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 21:39 UTC | AVENUE THERAPEUTICS, INC. ATXI · Entity 8537 | GiftCommon Stock | 14,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-042950 · tv500464_form4.xml · nonDerivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,663 F1 · shares: The 14,663 shares of restricted common stock will vest on August 7, 2021. F2 · balance_after: Includes 64,663 shares of restricted stock. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 19:15 UTC | IMMUNE PHARMACEUTICALS INC IMNP · Entity 151953 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001144204-17-004430 · v457813_form4.xml · derivative · entry 1 Paley Jeffrey · CIK 0001595327 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 500,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The stock options shall vest in equal quarterly installments over a one-year period from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.